Study confirms link between alcohol consumption, breast cancer risk...
In findings published in the journal Cancer, Epidemiology, Biomarkers & Prevention, UNC Lineberger Comprehensive Cancer Center researchers confirmed the link between alcohol consumption and breast cancer risk in a study in black women. The association has been seen in other studies drawn from majority white populations.
Adventure in the Face of Cancer
At 28 years old, Dave Carbonell was months away from completing his residency in Emergency Medicine at UNC. Then cancer struck—acute lymphoblastic leukemia. Today, after years of intense treatment, he’s cancer free, working as an Emergency Department physician in California and helping other young
‘Good’ bacteria is possible solution for unchecked infl...
In a study published in journal Nature Immunology, researchers led by UNC Lineberger member Jenny P.Y. Ting, PhD, describe how inflammation can go unchecked in the absence of a certain inflammation inhibitor called NLRP12. In a harmful feedback loop, this inflammation can upset the balance of bacteria living in the gut. Beneficial bacterial may be the key to reversing inflammation in the absence of this key regulator.
Earp, Ting recognized for career achievements in cancer research
H. Shelton Earp, MD, director of UNC Cancer Care and the Lineberger Professor of Cancer Research, and Jenny P.Y. Ting, PhD, UNC Lineberger member and William Rand Kenan Professor of Genetics, have been honored with the Hyman L. Battle Distinguished Cancer Research Award.
Measuring patients’ muscles to predict chemotherapy side effects
UNC Lineberger researchers Hy Muss, MD, Shlomit Strulov Shachar, MD, and colleagues report in the journal Clinical Cancer Research that a measure of muscle mass and muscle quality developed at UNC could potentially help doctors better identify patients at high risk for side effects that could require hospitalization.
Researchers unlock mechanism of drug resistance in aggressive breas...
UNC Lineberger researchers find how triple negative breast cancer cells are able to bypass treatment with trametinib, an FDA-approved drug. The researchers also used lab models of breast cancer to test a potential treatment approach that could prevent resistance.